US 12,281,330 B2
Adaptation of hollow-fiber-based cell culture technology for the manufacturing of (1) neo-islets, employed for the treatment of type 1 and type 2 diabetes mellitus, and (2) the generation of exosomes from various cell types, used in the treatment of different organ injuries and diseases
Christof Westenfelder, Salt Lake City, UT (US); and Anna L. Gooch, Salt Lake City, UT (US)
Assigned to SymbioCellTech, Salt Lake City, UT (US)
Appl. No. 16/646,112
Filed by SYMBIOCELLTECH, LLC, Salt Lake City, UT (US)
PCT Filed Sep. 7, 2018, PCT No. PCT/US2018/049950
§ 371(c)(1), (2) Date Mar. 10, 2020,
PCT Pub. No. WO2019/051225, PCT Pub. Date Mar. 14, 2019.
Claims priority of provisional application 62/556,888, filed on Sep. 11, 2017.
Prior Publication US 2020/0208115 A1, Jul. 2, 2020
Int. Cl. C12N 5/00 (2006.01); A61P 3/10 (2006.01); C12M 1/00 (2006.01); C12N 5/071 (2010.01); C12N 5/0775 (2010.01)
CPC C12N 5/0667 (2013.01) [A61P 3/10 (2018.01); C12M 29/10 (2013.01); C12N 5/0676 (2013.01); C12N 2521/00 (2013.01)] 7 Claims
 
1. A method for generating Neo Islets, the method comprising:
culturing expanding mesenchymal or adipose stem cells and pancreatic islet cells in a Hollow-Fiber-based Cell Expansion (HFCE) System;
forming, in the HFCE system, Neo Islets from the cultured mesenchymal or adipose stem cells and pancreatic islet cells; and
collecting the formed Neo Islets from the HFCE System.